Recursion Pharmaceuticals, Inc. (RXRX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Ben R. Taylor
|
CFO & President of Recursion UK | 751.49k | -- | 1977 |
|
Mr. Benjamin Mabey M.S.
|
Chief Technology Officer | -- | -- | 1983 |
|
Dr. David Hallett Ph.D.
|
Chief Scientific Officer | -- | -- | 1969 |
|
Mr. Nathan Hatfield J.D., M.B.A.
|
Chief Legal Officer & Corporate Secretary | -- | -- | -- |
|
Mr. Ryan Kelly
|
Chief Communications Officer | -- | -- | -- |
|
Ms. Erica Fox
|
Chief People and Impact Officer | -- | -- | -- |
|
Mr. Matthew Kinn M.B.A.
|
Chief Business Officer | -- | -- | -- |
|
Mr. Sid Jain
|
Senior Vice President of Clinical Development & Data Science | -- | -- | -- |
|
Dr. Vicki L. Goodman M.D.
|
Chief Medical Officer | -- | -- | 1971 |
|
Dr. Elizabeth Bruckheimer Ph.D.
|
Vice President of Clinical Development | -- | -- | -- |
Recursion Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 600
Description
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Corporate Governance
Upcoming Events
November 2, 2026 at 9:00 PM UTC
Recursion Pharmaceuticals, Inc. Earnings Date
